Artivion, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparisons are with Q1 2023 unless otherwise noted. Artivion develops and sells cardiovascular medical devices and provides cardiac and vascular tissue preservation services. Dollar amounts below are in millions unless stated otherwise.
Financial performance
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Revenue | $97.4 | $83.2 | +17%; +16% at constant currency |
| Gross profit / margin | $62.9 / 64.6% | $53.7 / 64.6% | Gross profit +17%; margin essentially flat |
| Operating income (loss) | $25.3 | $(3.9) | Improved |
| Net income (loss) | $7.5 | $(13.5) | Improved |
| Diluted earnings (loss) per share | $0.18 | $(0.33) | Improved |
| Operating cash flow | $(5.5) | $(6.2) | Cash used in both periods |
| Capital expenditures | $3.6 | $2.8 | Increased |
Revenue growth was broad-based: preservation services rose 26% to $26.3 million, medical-device product revenue rose 14% to $71.1 million, and aortic stent graft revenue increased 23% to $32.1 million. On-X revenue increased 11% to $19.7 million; surgical sealants increased 2% to $17.0 million. North America revenue grew 18% and EMEA 17% on a constant-currency basis; APAC declined 3%.
Operating expenses fell to $37.6 million from $57.6 million, primarily reflecting the change in fair value of Ascyrus contingent consideration. The $17.5 million fair-value reduction was recorded as business-development income in general, administrative, and marketing expense; Q1 2023 included a $4.8 million fair-value increase recorded as expense. The 2024 reduction was attributed primarily to a higher credit-risk spread following the new credit facilities. Results also included a $3.7 million loss on extinguishment of prior debt. These items materially affect the year-over-year earnings comparison.
Interest expense rose to $7.8 million from $6.1 million, principally due to higher rates on the January 2024 refinancing. Income tax expense was $5.2 million; the effective tax rate was 41%, compared with 52% in Q1 2023. Reported gross margin was 65% in both periods. The filing does not provide a clear adjusted or recurring profit measure.
Balance sheet, debt and liquidity
- Cash and cash equivalents were $51.1 million at March 31, 2024, down from $58.9 million at year-end; approximately 29% of cash was held outside the United States.
- Net working capital was $231.0 million and the current ratio was approximately 6:1, versus $222.8 million and 5:1 at December 31, 2023.
- Reported debt was $313.3 million net of unamortized issuance costs (gross loan balances of $320.4 million). This included $190 million of term debt, $30 million drawn on a $60 million revolving facility, and $100 million of convertible notes. Cash was $51.1 million.
- In January, Artivion refinanced its prior credit agreement with Ares facilities totaling $350 million: a $190 million initial term loan, $100 million delayed-draw term loan, and $60 million revolving facility. The delayed-draw facility remained undrawn. The facilities mature in January 2030, are interest-only with no scheduled principal repayment before maturity, and are secured by substantially all company assets, subject to exceptions.
- As of March 31, stated annual interest rates were 11.80% on the term loan facilities and 9.30% on the revolver. The $100 million 4.25% convertible notes mature July 1, 2025. The company reported a 3.79x total net leverage ratio, against a maximum covenant of 6.25x through Q4 2024 and 5.75x thereafter.
- Operating cash use was $5.5 million, including working-capital outflows, while investing cash use was $3.6 million. Financing cash flow was a net $0.7 million inflow after new borrowing, repayment of prior debt, and $10.0 million of debt issuance costs.
Changes, outlook and key risks
Management identified new products, new indications, international expansion, and business development as principal growth drivers. It expects cash from operations and existing cash to cover current operational liquidity needs for at least the next 12 months, while noting future needs for debt interest, clinical and R&D work, working capital, capital expenditures, and potential business development. No quantified revenue or earnings guidance is provided in the filing.
- Preservation-service revenue can fluctuate with tissue availability, processing yields, release timing, procedure demand, and competing alternatives. Management attributed the quarter’s increase mainly to higher average selling prices and, to a lesser extent, more tissues shipped.
- Regulatory and market-access risks include the European MDR transition and certification renewals; the Chord-X renewal remained outstanding, and the company was still transitioning PhotoFix certification. Artivion had resubmitted its BioGlue application in China and anticipated a response within the next year.
- NEXUS products are solely manufactured by Endospan in Israel. The company reported no material supply disruption to date but highlighted the continuing regional conflict and associated supply-chain risks. Other single- and sole-source suppliers also create interruption exposure.
- Other disclosed risks include competition, foreign-exchange and interest-rate movements, product and tissue liability, and clinical or regulatory delays. Management stated that no pending legal matter was currently believed likely to have a material adverse effect, while cautioning that litigation outcomes remain uncertain.
- Potential contingent payments include up to $100 million related to Ascyrus milestones and sales-based earn-outs, and up to $3 million for certain Baxter-related milestones. The Ascyrus contingent consideration is a Level 3 estimate based on unobservable assumptions, including a roughly 17% discount rate and anticipated milestone dates in 2025–2026.
Important facts for investors to verify
- How much of the 17% revenue growth reflects sustained demand and volume, versus currency, pricing, product mix, or customer ordering patterns?
- Whether operating cash flow improves as working-capital outflows unwind, given negative operating cash flow despite reported net income.
- Debt-service capacity under floating-rate borrowing, compliance with leverage covenants, and the plan for the July 2025 convertible-note maturity.
- How much of reported earnings depends on the volatile Ascyrus contingent-consideration remeasurement, and how future changes in estimates could affect results.
- Progress on European certifications, BioGlue regulatory approval in China, and continuity of supply for NEXUS and other products reliant on single-source suppliers.